Profile data is unavailable for this security.
About the company
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.
- Revenue in USD (TTM)131.00k
- Net income in USD-34.50m
- Incorporated2015
- Employees11.00
- LocationINmune Bio Inc225 Ne Mizner Blvd, Suite 640BOCA RATON 33432United StatesUSA
- Phone+1 (858) 964-3720
- Websitehttp://www.inmunebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Syros Pharmaceuticals Inc | 6.98m | -144.49m | 160.37m | 68.00 | -- | 10.65 | -- | 22.97 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Alpha Tau Medical Ltd | 0.00 | -28.95m | 160.53m | 121.00 | -- | 2.03 | -- | -- | -0.4165 | -0.4165 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -26.50 | -- | -28.08 | -- | -- | -- | -- | -- | -- | -- | 0.0653 | -- | -- | -- | 13.64 | -- | -- | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 161.29m | 179.00 | -- | 0.6894 | -- | 1.65 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Caribou Biosciences Inc | 33.40m | -115.26m | 161.67m | 158.00 | -- | 0.4709 | -- | 4.84 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 162.74m | 65.00 | -- | 1.57 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Galectin Therapeutics Inc | 0.00 | -44.78m | 162.83m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 162.85m | 1.00 | -- | 53.99 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 164.47m | 101.00 | -- | 8.86 | -- | 6.07 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Alimera Sciences Inc | 90.22m | -22.66m | 166.07m | 159.00 | -- | 4.08 | -- | 1.84 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
| Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 167.16m | 147.00 | -- | -- | -- | 1.39 | -0.1135 | -0.1135 | 0.69 | -0.1806 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| OptiNose Inc | 74.02m | -30.75m | 167.29m | 132.00 | -- | -- | -- | 2.26 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| INmune Bio Inc | 131.00k | -34.50m | 167.95m | 11.00 | -- | 5.25 | -- | 1,282.08 | -1.92 | -1.92 | 0.0073 | 1.62 | 0.0022 | -- | 0.0535 | 11,909.09 | -57.11 | -37.82 | -74.12 | -41.86 | -- | -- | -26,333.59 | -14,901.03 | -- | -16.97 | 0.2044 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 168.27m | 22.00 | -- | 3.39 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| X4 Pharmaceuticals Inc | 0.00 | -128.91m | 171.30m | 93.00 | -- | 165.34 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 171.35m | 53.00 | 11.03 | 3.69 | 10.13 | 3.62 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 173.60m | 75.00 | -- | 2.40 | -- | 21.69 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Data as of Jun 14 2024. Currency figures normalised to INmune Bio Inc's reporting currency: US Dollar USD
9.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 536.79k | 2.71% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 233.87k | 1.18% |
| MAI Capital Management LLCas of 31 Mar 2024 | 181.41k | 0.92% |
| Rhenman & Partners Asset Management ABas of 31 Mar 2024 | 178.28k | 0.90% |
| Geode Capital Management LLCas of 31 Mar 2024 | 170.80k | 0.86% |
| Millennium Management LLCas of 31 Mar 2024 | 159.19k | 0.81% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 154.83k | 0.78% |
| Janney Montgomery Scott LLC (Investment Management)as of 31 Mar 2024 | 140.91k | 0.71% |
| DWS Investment GmbHas of 31 Mar 2024 | 109.85k | 0.56% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 87.61k | 0.44% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
